In response to government pressure, Vertex Pharmaceuticals (VRTX) and the U.K.’s National Health Service made competing offers for access to cystic fibrosis treatments, but whether a deal can be reached to break a long-running impasse remains unclear.
The dispute, which has been underway for approximately four years, has roiled families across the country and, on a wider scale, has come to symbolize the growing friction between drug makers and governments over the rising cost of medicines. The proposals were made following a March hearing before Parliament that was held to try to break the logjam.
About the Author Reprints
